A Phase 4 interventional study of Anidulafungin and Voriconazole in Candidemia and Invasive Candidiasis, sponsored by Pfizer. Completed at 13 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-17.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing anidulafungin in Candidemia — none open to participants now, none under way, none of them phase 3. Anidulafungin · Candidemia.
Among the 11 studies testing anidulafungin in Candidemia, this one is the 8th largest by enrollment, is one of 5 that started in 2008, is one of 4 in phase 4, and was the 5th registered.
73 studies on the registry are indexed under Candidemia; 5 are open to participants now.
Browse Candidemia studies →None of the 11 studies testing anidulafungin in Candidemia is open now. The open studies under Candidemia, anywhere →
Anidulafungin: first FDA approval 2006 (ERAXIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 2 Candidemia studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 63 across 44 interventional studies indexed under Candidemia.
Median enrollment 70 across the 11 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
15 studies in Candidemia by Pfizer: none open now, none under way, none of them phase 3. Of 15 finished, 13 (87%) have results posted.
Among the 15 studies in Candidemia by Pfizer, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 6 that started in 2008, is one of 3 in phase 4, and was the 5th registered.
Pfizer’s Candidemia studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing anidulafungin in Candidemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 15 in Candidemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective is to estimate global response rate. Clinical, microbiological and global response rates and its 95% confidence intervals will be computed. No hypotheses will be tested.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presence of one or more of the following signs and symptoms of acute fungal infection within the prior 48 hours to initiation of study treatment:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Anidulafungin · Drug: Voriconazole
All patients will receive anidulafungin 200 mg IV dose on Day 1. On Day 2 and daily thereafter the patients will receive one daily IV dose of 100 mg of anidulafungin.
Also known as: Eraxis
Patients who complete a minimum of 5 days of IV treatment with anidulafungin may be switched to oral voriconazole 200 mg BID (or 100 mg BID if \<40 kg body weight) therapy on Day 5 and thereafter, starting with a loading dose of 400 mg BID (or 200 mg BID if \<40 kg body weight).
Also known as: Vfend
Number of Participants for Global Response (Based on Clinical and Microbiological Success or Failure) at End of Treatment
Clinical Success (cure=resolution of Candida signs and symptoms \[s/s\] or improvement=significant but incomplete resolution of s/s) or Failure (at least 3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological Success (eradication=negative culture for baseline Candida species (spp) or presumed eradication=follow-up (f/u) culture not available (n/a) and clinical outcome defined as success) or Failure (persistence=positive culture for at least 1 baseline Candida spp or presumed persistence=f/u culture n/a and clinical outcome defined as failure).
Time frame: End of Treatment (EOT) (up to Day 42)
Number of Participants for Global Response (Based on Clinical and Microbiological Success or Failure)
Clinical Success (cure=resolution of Candida signs and symptoms \[s/s\] or improvement=significant but incomplete resolution of s/s) or Failure (at least 3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological Success (eradication=negative culture for baseline Candida species (spp) or presumed eradication=follow-up (f/u) culture not available (n/a) and clinical outcome defined as success) or Failure (persistence=positive culture for at least 1 baseline Candida spp or presumed persistence=f/u culture n/a and clinical outcome defined as failure).
Time frame: End of Intravenous Treatment (EIVT) (up to Day 42), Week 2 Follow-up
Number of Participants for Global Response Per Type of Candida Species Isolated at Baseline: EIVT
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Categorized as global Success if both clinical and microbiological response=success; Failure defined as all other combinations. Global response at EIVT was assessed per the type of Candida species that was isolated at the baseline visit.
Time frame: Baseline, EIVT (up to Day 42)
Number of Participants for Global Response Per Type of Candida Species Isolated at Baseline: EOT
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Categorized as global Success if both clinical and microbiological response=success; Failure defined as all other combinations. Global response at EOT was assessed per the type of Candida species that was isolated at the baseline visit.
Time frame: Baseline, EOT (up to Day 42)
Number of Participants for Global Response Per Type of Candida Species Isolated at Baseline: Week 2 Follow-up
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Categorized as global Success if both clinical and microbiological response=success; Failure defined as all other combinations. Global response at Week 2 Follow-up was assessed per the type of Candida species that was isolated at the baseline visit.
Time frame: Baseline, Week 2 Follow-up
Number of Participants for Global Response for Pre-specified Baseline Risk Factors Subgroups of Interest: EOT
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Global response at EOT was assessed for participants categorized with baseline risk factors (Yes or No status) for Intensive Care Unit (ICU) stay ≥ 4 days, mechanical ventilation, broad spectrum antibiotics (antibiotics), central venous (CV) catheter, total parental nutrition (TPN), dialysis, abdominal surgery, solid organ transplant, renal insufficiency, chemotherapy, pancreatitis, systemic steroids or immunosuppressives (Systemic steroids/immunos), neutropenic status, or elderly.
Time frame: Baseline, EOT (up to Day 42)
Number of Participants for Global Response for Baseline Risk Factors for Candidemia and Invasive Candidiasis: EIVT
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Global response at EIVT was assessed for participants categorized with baseline risk factors for Candidemia and Invasive Candidiasis: ICU stay ≥ 4 days, mechanical ventilation, broad spectrum antibiotics (antibiotics), central venous (CV) catheter, total parental nutrition (TPN), dialysis, abdominal surgery, solid organ transplant, renal insufficiency, chemotherapy, pancreatitis, systemic steroids or immunosuppressives (Systemic steroids/immunos), neutropenic status, or elderly.
Time frame: EIVT (up to Day 42)
Number of Participants for Global Response for Baseline Risk Factors for Candidemia and Invasive Candidiasis: Week 2 Follow-up
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Global response at Week 2 F/U was assessed for participants categorized with baseline risk factors for Candidemia and Invasive Candidiasis: ICU stay ≥ 4 days, mechanical ventilation, broad spectrum antibiotics (antibiotics), central venous (CV) catheter, total parental nutrition (TPN), dialysis, abdominal surgery, solid organ transplant, renal insufficiency, chemotherapy, pancreatitis, systemic steroids or immunosuppressives (Systemic steroids/immunos), neutropenic status, or elderly.
Time frame: Baseline, Week 2 Follow-up (F/U)
Number of Participants for Global Response by Acute Physiological Assessment and Chronic Health Evaluation II (APACHE II) Score
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Categorized as global Success if both clinical and microbiological response=success; Failure defined as all other combinations. Global response assessed as APACHE II score \<20 (less affected) or ≥20 (more severe). APACHE II assesses severity of illness in acutely ill participants; measurements computed for physiologic variables were transformed to integer score ranging 0 (normal) to 71 (more severe). Higher scores indicate more severe disease and higher risk of death.
Time frame: EIVT (up to Day 42), EOT (up to Day 42), Week 2 Follow-up
Number of Participants Per Survival Status (Alive or Dead) on Day 30
Time frame: Day 30
Number of Participants With Death Attributable (Yes or No) to Candidemia or Invasive Candidiasis
Death is attributable to Candidemia or Invasive Candidiasis if investigator recorded "disease under study" as cause of death. Candidemia (positive blood culture) or Invasive Cadidiasis (yeast cells in histopathological or cytopathological exam). Week 6 Follow-up visit conducted by phone.
Time frame: Baseline to Week 6 Follow-up
Time to Negative Blood, Specimen, or Tissue Culture
Defined as time from first drug administratin to date of earliest recorded documentation of negative blood, specimen, or tissue culture (absence of Candidemia or Invasive Candidiasis). Candidemia (positive blood culture) or Invasive Cadidiasis (yeast cells in histopathological or cytopathological exam).
Time frame: Baseline to Week 2 Follow-up
Duration of Exposure to Intravenous Anidulafungin Prior to Switch to Oral Voriconazole Treatment
Defined as time in days from first intravenous administration of Anidulafungin to the date of earliest recorded documentation of switch to oral Voriconazole treatment. Participants received at least 5 days (and a maximum of 42 days) of IV Anidulafungin; after this, they may continue treatment with oral Voriconazole for at least 14 days from the day of last positive culture up to a maximum of 42 days.
Time frame: Baseline to Day 42
Length of Hospital Stay
Defined as the number of days from date of first drug administration to date of first hospital discharge if participant was discharged to home or other location. Week 6 Follow-up visit conducted by phone.
Time frame: Baseline to Week 6 Follow-up
Length of Stay in Intensive Care Unit (ICU)
Defined as the number of days from date of first drug administration to date of first ICU discharge. Week 6 Follow-up visit conducted by phone.
Time frame: Baseline up to Week 6 Follow-up
Change From Baseline in Vital Signs: Supine Blood Pressure
Supine systolic and diastolic blood pressure BP) measured as millimeters of mercury (mmHg).
Time frame: Baseline to Week 2 Follow-up
Change From Baseline in Vital Signs: Supine Heart Rate
Supine heart rate measured as beats per minute (bpm).
Time frame: Baseline to Week 2 Follow-up
Change From Baseline in Vital Signs: Weight
Weight measured as kilograms (kg).
Time frame: Baseline to Week 2 Follow-up
Change From Baseline in Vital Signs: Temperature
Temperature measured as degrees of Celsius (C).
Time frame: Baseline to Week 2 Follow-up
Change From Baseline in Vital Signs: Respiration Rate
Respiration rate measured as respirations per minute (resp/min).
Time frame: Baseline to Week 2 Follow-up
Change From Baseline in Chemistry Laboratory Test Data (Measured as mg/dL)
Chemistry laboratory test data measured as milligrams per deciliter (mg/dL).
Time frame: Baseline to Week 2 Follow-up
Change From Baseline in Chemistry Laboratory Test Data (Measured as IU/L)
Chemistry laboratory test data measured as international units per (IU/L).
Time frame: Baseline to Week 2 Follow-up
| Milestone | Anidulafungin-Voriconazole |
|---|---|
| Started | 54 |
| Completed | 22 |
| Not completed | 32 |
| Withdrew: Death | 21 |
| Withdrew: Adverse event | 2 |
| Withdrew: Lack of efficacy | 4 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Other | 3 |
| Withdrew: Withdrawal by subject | 1 |
Clinical Success (cure=resolution of Candida signs and symptoms \[s/s\] or improvement=significant but incomplete resolution of s/s) or Failure (at least 3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological Success (eradication=negative culture for baseline Candida species (spp) or presumed eradication=follow-up (f/u) culture not available (n/a) and clinical outcome defined as success) or Failure (persistence=positive culture for at least 1 baseline Candida spp or presumed persistence=f/u culture n/a and clinical outcome defined as failure).
| participants | Anidulafungin-Voriconazole |
|---|---|
| Success | 26 (44.6 to 73.6) |
| Failure | 18 (NA to NA) |
Clinical Success (cure=resolution of Candida signs and symptoms \[s/s\] or improvement=significant but incomplete resolution of s/s) or Failure (at least 3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological Success (eradication=negative culture for baseline Candida species (spp) or presumed eradication=follow-up (f/u) culture not available (n/a) and clinical outcome defined as success) or Failure (persistence=positive culture for at least 1 baseline Candida spp or presumed persistence=f/u culture n/a and clinical outcome defined as failure).
| participants | Anidulafungin-Voriconazole |
|---|---|
| EIVT Success | 26 (44.6 to 73.6) |
| EIVT Failure | 18 (NA to NA) |
| Week 2 Follow-up Success | 21 (33.0 to 62.5) |
| Week 2 Follow-up Failure | 23 (NA to NA) |
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Categorized as global Success if both clinical and microbiological response=success; Failure defined as all other combinations. Global response at EIVT was assessed per the type of Candida species that was isolated at the baseline visit.
| participants | Anidulafungin-Voriconazole |
|---|---|
| Candida albicans: Success | 11 (31.0 to 73.7) |
| Candida albicans: Failure | 10 (NA to NA) |
| Candida famata: Success | 1 (0.0 to 100.0) |
| Candida famata: Failure | 1 (NA to NA) |
| Candida glabrata: Success | 2 (13.3 to 100.0) |
| Candida glabrata: Failure | 1 (NA to NA) |
| Candida guilliermondii: Success | 1 (NA to NA) |
| Candida guilliermondii: Failure | 0 (NA to NA) |
| Candida krusei: Success | 2 (13.3 to 100.0) |
| Candida krusei: Failure | 1 (NA to NA) |
| Candida parapsilosis: Success | 1 (0.0 to 46.5) |
| Candida parapsilosis: Failure | 5 (NA to NA) |
| Candida pelliculosa: Success | 1 (NA to NA) |
| Candida pelliculosa: Failure | 0 (NA to NA) |
| Candida tropicalis: Success | 8 (55.2 to 100.0) |
| Candida tropicalis: Failure | 2 (NA to NA) |
| Unidentifiable: Success | 4 (20.5 to 93.8) |
| Unidentifiable: Failure | 3 (NA to NA) |
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Categorized as global Success if both clinical and microbiological response=success; Failure defined as all other combinations. Global response at EOT was assessed per the type of Candida species that was isolated at the baseline visit.
| participants | Anidulafungin-Voriconazole |
|---|---|
| Candida albicans: Success | 11 (31.0 to 73.7) |
| Candida albicans: Failure | 10 (NA to NA) |
| Candida famata: Success | 0 (NA to NA) |
| Candida famata: Failure | 2 (NA to NA) |
| Candida glabrata: Success | 2 (13.3 to 100.0) |
| Candida glabrata: Failure | 1 (NA to NA) |
| Candida guilliermondii: Success | 1 (NA to NA) |
| Candida guilliermondii: Failure | 0 (NA to NA) |
| Candida krusei: Success | 2 (13.3 to 100.0) |
| Candida krusei: Failure | 1 (NA to NA) |
| Candida parapsilosis: Success | 1 (0.0 to 46.5) |
| Candida parapsilosis: Failure | 5 (NA to NA) |
| Candida pelliculosa: Success | 1 (NA to NA) |
| Candida pelliculosa: Failure | 0 (NA to NA) |
| Candida tropicalis: Success | 8 (55.2 to 100.0) |
| Candida tropicalis: Failure | 2 (NA to NA) |
| Unidentifiable: Success | 4 (20.5 to 93.8) |
| Unidentifiable: Failure | 3 (NA to NA) |
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Categorized as global Success if both clinical and microbiological response=success; Failure defined as all other combinations. Global response at Week 2 Follow-up was assessed per the type of Candida species that was isolated at the baseline visit.
| participants | Anidulafungin-Voriconazole |
|---|---|
| Candida albicans: Success | 10 (26.3 to 69.0) |
| Candida albicans: Failure | 11 (NA to NA) |
| Candida famata: Success | 0 (NA to NA) |
| Candida famata: Failure | 2 (NA to NA) |
| Candida glabrata: Success | 3 (NA to NA) |
| Candida glabrata: Failure | 0 (NA to NA) |
| Candida guilliermondii: Success | 1 (NA to NA) |
| Candida guilliermondii: Failure | 0 (NA to NA) |
| Candida krusei: Success | 2 (13.3 to 100.0) |
| Candida krusei: Failure | 1 (NA to NA) |
| Candida parapsilosis: Success | 0 (NA to NA) |
| Candida parapsilosis: Failure | 6 (NA to NA) |
| Candida pelliculosa: Success | 1 (NA to NA) |
| Candida pelliculosa: Failure | 0 (NA to NA) |
| Candida tropicalis: Success | 7 (41.6 to 98.4) |
| Candida tropicalis: Failure | 3 (NA to NA) |
| Unidentifiable: Success | 2 (0.0 to 62.0) |
| Unidentifiable: Failure | 5 (NA to NA) |
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Global response at EOT was assessed for participants categorized with baseline risk factors (Yes or No status) for Intensive Care Unit (ICU) stay ≥ 4 days, mechanical ventilation, broad spectrum antibiotics (antibiotics), central venous (CV) catheter, total parental nutrition (TPN), dialysis, abdominal surgery, solid organ transplant, renal insufficiency, chemotherapy, pancreatitis, systemic steroids or immunosuppressives (Systemic steroids/immunos), neutropenic status, or elderly.
| participants | Anidulafungin-Voriconazole |
|---|---|
| ICU stay ≥ 4 days (Yes): Success | 18 (39.1 to 73.4) |
| ICU stay ≥ 4 days (Yes): Failure | 14 (NA to NA) |
| ICU stay ≥ 4 days (No): Success | 8 (40.0 to 93.3) |
| ICU stay ≥ 4 days (No): Failure | 4 (NA to NA) |
| Mechanical ventilation (Yes): Success | 18 (37.6 to 71.5) |
| Mechanical ventilation (Yes): Failure | 15 (NA to NA) |
| Mechanical ventilation (No): Success | 8 (46.4 to 99.0) |
| Mechanical ventilation (No): Failure | 3 (NA to NA) |
| Antibiotics (Yes): Success | 22 (40.8 to 72.0) |
| Antibiotics (Yes): Failure | 17 (NA to NA) |
| Antibiotics (No): Success | 4 (44.9 to 100.0) |
| Antibiotics (No): Failure | 1 (NA to NA) |
| CV Catheter (Yes): Success | 21 (39.5 to 71.1) |
| CV Catheter (Yes): Failure | 17 (NA to NA) |
| CV Catheter (No): Success | 5 (53.5 to 100.0) |
| CV Catheter (No): Failure | 1 (NA to NA) |
| TPN (Yes): Success | 5 (12.0 to 64.9) |
| TPN (Yes): Failure | 8 (NA to NA) |
| TPN (No): Success | 21 (51.3 to 84.2) |
| TPN (No): Failure | 10 (NA to NA) |
| Dialysis (Yes): Success | 3 (6.2 to 79.5) |
| Dialysis (Yes): Failure | 4 (NA to NA) |
| Dialysis (No): Success | 23 (46.5 to 77.8) |
| Dialysis (No): Failure | 14 (NA to NA) |
| Abdominal surgery (Yes): Success | 11 (35.7 to 80.1) |
| Abdominal surgery (Yes): Failure | 8 (NA to NA) |
| Abdominal surgery (No): Success | 15 (40.8 to 79.2) |
| Abdominal surgery (No): Failure | 10 (NA to NA) |
| Solid organ transplant (No): Success | 26 (44.6 to 73.6) |
| Solid organ transplant (No): Failure | 18 (NA to NA) |
| Renal insufficiency (Yes): Success | 3 (6.2 to 79.5) |
| Renal insufficiency (Yes): Failure | 4 (NA to NA) |
| Renal insufficiency (No): Success | 23 (46.5 to 77.8) |
| Renal insufficiency (No): Failure | 14 (NA to NA) |
| Chemotherapy (Yes): Success | 1 (NA to NA) |
| Chemotherapy (Yes): Failure | 0 (NA to NA) |
| Chemotherapy (No): Success | 25 (43.4 to 72.9) |
| Chemotherapy (No): Failure | 18 (NA to NA) |
| Pancreatitis (Yes): Success | 1 (0.0 to 55.1) |
| Pancreatitis (Yes): Failure | 4 (NA to NA) |
| Pancreatitis (No): Success | 25 (49.0 to 79.2) |
| Pancreatitis (No): Failure | 14 (NA to NA) |
| Systemic steroids/immunos (Yes): Success | 6 (21.7 to 78.3) |
| Systemic steroids/immunos (Yes): Failure | 6 (NA to NA) |
| Systemic steroids/immunos (No): Success | 20 (45.7 to 79.3) |
| Systemic steroids/immunos (No): Failure | 12 (NA to NA) |
| Neutropenic: Success | 2 (13.3 to 100.0) |
| Neutropenic: Failure | 1 (NA to NA) |
| Non-neutropenic: Success | 18 (44.4 to 79.7) |
| Non-neutropenic: Failure | 11 (NA to NA) |
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Global response at EIVT was assessed for participants categorized with baseline risk factors for Candidemia and Invasive Candidiasis: ICU stay ≥ 4 days, mechanical ventilation, broad spectrum antibiotics (antibiotics), central venous (CV) catheter, total parental nutrition (TPN), dialysis, abdominal surgery, solid organ transplant, renal insufficiency, chemotherapy, pancreatitis, systemic steroids or immunosuppressives (Systemic steroids/immunos), neutropenic status, or elderly.
| participants | Anidulafungin-Voriconazole |
|---|---|
| ICU stay ≥ 4 days (Yes): Success | 18 (39.1 to 73.4) |
| ICU stay ≥ 4 days (Yes): Failure | 14 (NA to NA) |
| ICU stay ≥ 4 days (No): Success | 8 (40.0 to 93.3) |
| ICU stay ≥ 4 days (No): Failure | 4 (NA to NA) |
| Mechanical ventilation (Yes): Success | 18 (37.6 to 71.5) |
| Mechanical ventilation (Yes): Failure | 15 (NA to NA) |
| Mechanical ventilation (No): Success | 8 (46.4 to 99.0) |
| Mechanical ventilation (No): Failure | 3 (NA to NA) |
| Antibiotics (Yes): Success | 22 (40.8 to 72.0) |
| Antibiotics (Yes): Failure | 17 (NA to NA) |
| Antibiotics (No): Success | 4 (44.9 to 100.0) |
| Antibiotics (No): Failure | 1 (NA to NA) |
| CV Catheter (Yes): Success | 21 (39.5 to 71.1) |
| CV Catheter (Yes): Failure | 17 (NA to NA) |
| CV Catheter (No): Success | 5 (53.5 to 100.0) |
| CV Catheter (No): Failure | 1 (NA to NA) |
| TPN (Yes): Success | 6 (19.1 to 73.3) |
| TPN (Yes): Failure | 7 (NA to NA) |
| TPN (No): Success | 20 (47.7 to 81.4) |
| TPN (No): Failure | 11 (NA to NA) |
| Dialysis (Yes): Success | 3 (6.2 to 79.5) |
| Dialysis (Yes): Failure | 4 (NA to NA) |
| Dialysis (No): Success | 23 (46.5 to 77.8) |
| Dialysis (No): Failure | 14 (NA to NA) |
| Abdominal surgery (Yes): Success | 12 (41.5 to 84.8) |
| Abdominal surgery (Yes): Failure | 7 (NA to NA) |
| Abdominal surgery (No): Success | 14 (36.5 to 75.5) |
| Abdominal surgery (No): Failure | 11 (NA to NA) |
| Solid organ transplant (No): Success | 26 (44.6 to 73.6) |
| Solid organ transplant (No): Failure | 18 (NA to NA) |
| Renal insufficiency (Yes): Success | 3 (6.2 to 79.5) |
| Renal insufficiency (Yes): Failure | 4 (NA to NA) |
| Renal insufficiency (No): Success | 23 (46.5 to 77.8) |
| Renal insufficiency (No): Failure | 14 (NA to NA) |
| Chemotherapy (Yes): Success | 1 (NA to NA) |
| Chemotherapy (Yes): Failure | 0 (NA to NA) |
| Chemotherapy (No): Success | 25 (43.4 to 72.9) |
| Chemotherapy (No): Failure | 18 (NA to NA) |
| Pancreatitis (Yes): Success | 2 (0.0 to 82.9) |
| Pancreatitis (Yes): Failure | 3 (NA to NA) |
| Pancreatitis (No): Success | 24 (46.3 to 76.8) |
| Pancreatitis (No): Failure | 15 (NA to NA) |
| Systemic steroids/immunos (Yes): Success | 7 (30.4 to 86.2) |
| Systemic steroids/immunos (Yes): Failure | 5 (NA to NA) |
| Systemic steroids/immunos (No): Success | 19 (42.4 to 76.4) |
| Systemic steroids/immunos (No): Failure | 13 (NA to NA) |
| Neutropenic: Success | 2 (13.3 to 100.0) |
| Neutropenic: Failure | 1 (NA to NA) |
| Non-neutropenic: Success | 18 (44.4 to 79.7) |
| Non-neutropenic: Failure | 11 (NA to NA) |
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Global response at Week 2 F/U was assessed for participants categorized with baseline risk factors for Candidemia and Invasive Candidiasis: ICU stay ≥ 4 days, mechanical ventilation, broad spectrum antibiotics (antibiotics), central venous (CV) catheter, total parental nutrition (TPN), dialysis, abdominal surgery, solid organ transplant, renal insufficiency, chemotherapy, pancreatitis, systemic steroids or immunosuppressives (Systemic steroids/immunos), neutropenic status, or elderly.
| participants | Anidulafungin-Voriconazole |
|---|---|
| ICU stay ≥ 4 days (Yes): Success | 12 (20.7 to 54.3) |
| ICU stay ≥ 4 days (Yes): Failure | 20 (NA to NA) |
| ICU stay ≥ 4 days (No): Success | 9 (50.5 to 99.5) |
| ICU stay ≥ 4 days (No): Failure | 3 (NA to NA) |
| Mechanical ventilation (Yes): Success | 13 (22.7 to 56.1) |
| Mechanical ventilation (Yes): Failure | 20 (NA to NA) |
| Mechanical ventilation (No): Success | 8 (46.4 to 99.0) |
| Mechanical ventilation (No): Failure | 3 (NA to NA) |
| Antibiotics (Yes): Success | 19 (33.0 to 64.4) |
| Antibiotics (Yes): Failure | 20 (NA to NA) |
| Antibiotics (No): Success | 2 (0.0 to 82.9) |
| Antibiotics (No): Failure | 3 (NA to NA) |
| CV Catheter (Yes): Success | 18 (31.5 to 63.2) |
| CV Catheter (Yes): Failure | 20 (NA to NA) |
| CV Catheter (No): Success | 3 (10.0 to 90.0) |
| CV Catheter (No): Failure | 3 (NA to NA) |
| TPN (Yes): Success | 5 (12.0 to 64.9) |
| TPN (Yes): Failure | 8 (NA to NA) |
| TPN (No): Success | 16 (34.0 to 69.2) |
| TPN (No): Failure | 15 (NA to NA) |
| Dialysis (Yes): Success | 1 (0.0 to 40.2) |
| Dialysis (Yes): Failure | 6 (NA to NA) |
| Dialysis (No): Success | 20 (38.0 to 70.1) |
| Dialysis (No): Failure | 17 (NA to NA) |
| Abdominal surgery (Yes): Success | 8 (19.9 to 64.3) |
| Abdominal surgery (Yes): Failure | 11 (NA to NA) |
| Abdominal surgery (No): Success | 13 (32.4 to 71.6) |
| Abdominal surgery (No): Failure | 12 (NA to NA) |
| Solid organ transplant (No): Success | 21 (33.0 to 62.5) |
| Solid organ transplant (No): Failure | 23 (NA to NA) |
| Renal insufficiency (Yes): Success | 1 (0.0 to 40.2) |
| Renal insufficiency (Yes): Failure | 6 (NA to NA) |
| Renal insufficiency (No): Success | 20 (38.0 to 70.1) |
| Renal insufficiency (No): Failure | 17 (NA to NA) |
| Chemotherapy (Yes): Success | 1 (NA to NA) |
| Chemotherapy (Yes): Failure | 0 (NA to NA) |
| Chemotherapy (No): Success | 20 (31.6 to 61.4) |
| Chemotherapy (No): Failure | 23 (NA to NA) |
| Pancreatitis (Yes): Success | 2 (0.0 to 82.9) |
| Pancreatitis (Yes): Failure | 3 (NA to NA) |
| Pancreatitis (No): Success | 19 (33.0 to 64.4) |
| Pancreatitis (No): Failure | 20 (NA to NA) |
| Systemic steroids/immunos (Yes): Success | 5 (13.8 to 69.6) |
| Systemic steroids/immunos (Yes): Failure | 7 (NA to NA) |
| Systemic steroids/immunos (No): Success | 16 (32.7 to 67.3) |
| Systemic steroids/immunos (No): Failure | 16 (NA to NA) |
| Neutropenic: Success | 2 (13.3 to 100.0) |
| Neutropenic: Failure | 1 (NA to NA) |
| Non-neutropenic: Success | 15 (33.5 to 69.9) |
| Non-neutropenic: Failure | 14 (NA to NA) |
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Categorized as global Success if both clinical and microbiological response=success; Failure defined as all other combinations. Global response assessed as APACHE II score \<20 (less affected) or ≥20 (more severe). APACHE II assesses severity of illness in acutely ill participants; measurements computed for physiologic variables were transformed to integer score ranging 0 (normal) to 71 (more severe). Higher scores indicate more severe disease and higher risk of death.
| participants | Anidulafungin-Voriconazole |
|---|---|
| APACHE <20 (EIVT): Success | 24 (53.2 to 84.0) |
| APACHE <20 (EIVT): Failure | 11 (NA to NA) |
| APACHE ≥20 (EIVT): Success | 2 (0.0 to 49.4) |
| APACHE ≥20 (EIVT): Failure | 7 (NA to NA) |
| APACHE <20 (EOT): Success | 25 (56.5 to 86.4) |
| APACHE <20 (EOT): Failure | 10 (NA to NA) |
| APACHE ≥20 (EOT): Success | 1 (0.0 to 31.6) |
| APACHE ≥20 (EOT): Failure | 8 (NA to NA) |
| APACHE <20 (Week 2 F/U): Success | 20 (40.7 to 73.5) |
| APACHE <20 (Week 2 F/U): Failure | 15 (NA to NA) |
| APACHE ≥20 (Week 2 F/U): Success | 1 (0.0 to 31.6) |
| APACHE ≥20 (Week 2 F/U): Failure | 8 (NA to NA) |
| participants | Anidulafungin-Voriconazole |
|---|---|
| Alive | 25 |
| Dead | 19 |
Death is attributable to Candidemia or Invasive Candidiasis if investigator recorded "disease under study" as cause of death. Candidemia (positive blood culture) or Invasive Cadidiasis (yeast cells in histopathological or cytopathological exam). Week 6 Follow-up visit conducted by phone.
| participants | Anidulafungin-Voriconazole |
|---|---|
| Attributable death (Yes) | 4 |
| Attributable death (No) | 19 |
Defined as time from first drug administratin to date of earliest recorded documentation of negative blood, specimen, or tissue culture (absence of Candidemia or Invasive Candidiasis). Candidemia (positive blood culture) or Invasive Cadidiasis (yeast cells in histopathological or cytopathological exam).
No measurements were reported for this outcome.
Defined as time in days from first intravenous administration of Anidulafungin to the date of earliest recorded documentation of switch to oral Voriconazole treatment. Participants received at least 5 days (and a maximum of 42 days) of IV Anidulafungin; after this, they may continue treatment with oral Voriconazole for at least 14 days from the day of last positive culture up to a maximum of 42 days.
| days | Anidulafungin-Voriconazole |
|---|---|
| Duration of Exposure to Intravenous Anidulafungin Prior to Switch to Oral Voriconazole Treatment | 10.0 (1 to 28) |
Defined as the number of days from date of first drug administration to date of first hospital discharge if participant was discharged to home or other location. Week 6 Follow-up visit conducted by phone.
No measurements were reported for this outcome.
Defined as the number of days from date of first drug administration to date of first ICU discharge. Week 6 Follow-up visit conducted by phone.
| Days | Anidulafungin-Voriconazole |
|---|---|
| Length of Stay in Intensive Care Unit (ICU) | 16.0 (8.0 to 29.0) |
Supine systolic and diastolic blood pressure BP) measured as millimeters of mercury (mmHg).
| mmHg | Anidulafungin-Voriconazole |
|---|---|
| Baseline median: supine systolic BP | 120.0 (NA to NA) |
| Change from baseline: supine systolic BP | 0.00 (NA to NA) |
| Baseline median: supine diastolic BP | 66.0 (NA to NA) |
| Change from baseline: supine diastolic BP | 0.00 (NA to NA) |
Supine heart rate measured as beats per minute (bpm).
| bpm | Anidulafungin-Voriconazole |
|---|---|
| Baseline median: supine heart rate | 97.5 (NA to NA) |
| Change from baseline: supine heart rate | 3.00 (NA to NA) |
Weight measured as kilograms (kg).
| kg | Anidulafungin-Voriconazole |
|---|---|
| Baseline median: weight | 65.0 (NA to NA) |
| Change from baseline: weight | -0.70 (NA to NA) |
Temperature measured as degrees of Celsius (C).
| Degrees of Celsius | Anidulafungin-Voriconazole |
|---|---|
| Baseline median: temperature | 37.5 (NA to NA) |
| Change from baseline: temperature | -0.30 (NA to NA) |
Respiration rate measured as respirations per minute (resp/min).
| resp/min | Anidulafungin-Voriconazole |
|---|---|
| Baseline median: respiration rate | 20.0 (NA to NA) |
| Change from baseline: respiration rate | -0.50 (NA to NA) |
Chemistry laboratory test data measured as milligrams per deciliter (mg/dL).
| mg/dL | Anidulafungin-Voriconazole |
|---|---|
| Baseline median: total bilirubin (n=19) | 0.6 (NA to NA) |
| Change from baseline: total bilirubin | -0.2 (NA to NA) |
| Baseline median: direct bilirubin (n=19) | 0.2 (NA to NA) |
| Change from baseline: direct bilirubin | -0.1 (NA to NA) |
| Baseline median: indirect bilirubin (n=17) | 0.3 (NA to NA) |
| Change from baseline: indirect bilirubin | 0.0 (NA to NA) |
| Baseline median: blood urea nitrogen (n=25) | 37.4 (NA to NA) |
| Change from baseline: blood urea nitrogen | -4.8 (NA to NA) |
| Baseline median: creatinine (n=27) | 0.8 (NA to NA) |
| Change from baseline: creatinine | 0.0 (NA to NA) |
| Baseline median: glucose (n=24) | 99 (NA to NA) |
| Change from baseline: glucose | -6 (NA to NA) |
Chemistry laboratory test data measured as international units per (IU/L).
| IU/L | Anidulafungin-Voriconazole |
|---|---|
| Baseline median: aspartate aminotransferase (n=18) | 43 (NA to NA) |
| Change from baseline: aspartate aminotransferase | -18 (NA to NA) |
| Baseline median: alanine aminotransferase (n=16) | 45 (NA to NA) |
| Change from baseline: alanine aminotransferase | -5 (NA to NA) |
| Baseline median: lactate dehydrogenase (n=13) | 536 (NA to NA) |
| Change from baseline: lactate dehydrogenase | -160 (NA to NA) |
| Baseline median: alkaline phosphatase (n=17) | 114 (NA to NA) |
| Change from baseline: alkaline phosphatase | 26 (NA to NA) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Anidulafungin-Voriconazole | — | 29/54 (53.7%) | 26/54 (48.1%) |
| Event | Anidulafungin-Voriconazole |
|---|---|
| Septic shockInfections and infestations | 11/54 |
| Cardio-respiratory arrestCardiac disorders | 4/54 |
| Multi-organ disorderGeneral disorders | 4/54 |
| DeathGeneral disorders | 3/54 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 3/54 |
| Cardiac arrestCardiac disorders | 2/54 |
| Renal failureRenal and urinary disorders | 2/54 |
| HypotensionVascular disorders | 2/54 |
| Shock haemorrhagicVascular disorders | 2/54 |
| Blood disorderBlood and lymphatic system disorders | 1/54 |
| Event | Anidulafungin-Voriconazole |
|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 10/54 |
| AnaemiaBlood and lymphatic system disorders | 5/54 |
| PyrexiaGeneral disorders | 4/54 |
| HypertensionVascular disorders | 4/54 |
| LeukopeniaBlood and lymphatic system disorders | 3/54 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/54 |
| DiarrhoeaGastrointestinal disorders | 3/54 |
| VomitingGastrointestinal disorders | 3/54 |
| HyperglycaemiaMetabolism and nutrition disorders | 3/54 |
| HyperkalaemiaMetabolism and nutrition disorders | 3/54 |
| Age, Customized(participants) | Anidulafungin-Voriconazole |
|---|---|
| Between 18 and 44 years | 18 |
| Between 45 and 64 years | 18 |
| ≥ 65 years | 18 |
| Sex: Female, Male(Participants) | Anidulafungin-Voriconazole |
|---|---|
| Female | 32 |
| Male | 22 |
The record gives a start of Feb 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Anidulafungin · Voriconazole